pms-nifedipine er tablet (extended-release)
pharmascience inc - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
mylan-nifedipine extended release tablet (extended-release)
mylan pharmaceuticals ulc - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
nifedipine- nifedipine capsule, liquid filled
american health packaging - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - nifedipine capsules, usp are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsules, usp are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers an
nu-nifedipine-pa tablet (extended-release)
nu-pharm inc - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
nifedipine capsule
leading pharma, llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 20 mg - nifedipine capsules, usp (nifedipine) is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine capsules, usp may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine capsules, usp is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate
nifedipine er tablet (extended-release)
pro doc limitee - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
adalat 20
bayer new zealand limited - nifedipine 20mg - modified release tablet - 20 mg - active: nifedipine 20mg excipient: hypromellose iron oxide red lactose monohydrate macrogol 4000 magnesium stearate maize starch microcrystalline cellulose polysorbate 80 titanium dioxide - indicated for treatment of coronary heart disease, chronic stable angina pectoris (angina of effort) and hypertension.
nyefax retard
douglas pharmaceuticals limited - nifedipine 20mg; - modified release tablet - 20 mg - active: nifedipine 20mg excipient: iron oxide black iron oxide red lactose monohydrate macrogol 4000 magnesium stearate methylcellulose microcrystalline cellulose polysorbate 80 pregelatinised maize starch purified water titanium dioxide
adalat retard 20mg prolonged-release tablets
bayer limited - nifedipine - tablet prolonged release - 20 mg milligram - nifedipine
nifedipine capsule, liquid filled
actavis pharma, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - nifedipine capsules, usp are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsules, usp are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers an